A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
An Open-label, Safety and Tolerability Phase 1b Trial of CAN04, a Fully Humanized Anti-IL1RAP Monoclonal Antibody, and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study aims to establish a recommended dose of CAN04 in combination with the standard dose of pembrolizumab (Part 1), and in combination with pembrolizumab standard dose, and Standard of Care carboplatin and pemetrexed (Part 2 - subjects with stage IV, non-squamous metastatic NSCLC). CAN04, pembrolizumab. carboplatin and pemetrexed will be administered intravenously.
Frequency of TEAEs (treatment-emergent adverse events) (Part 1)
Serum concentrations of CAN04 and pembrolizumab (Part 1)
Carcinoma, Non-Small-Cell Lung
Study Arms / Comparison Groups
CAN04 and pembrolizumab (Part 1)
Description: Subjects will receive weekly doses of CAN04 in combination with pembrolizumab given as standard regimen
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
September 24, 2020
Primary Completion Date
Inclusion Criteria (Part 1): - Subjects with metastatic or locally advanced, incurable non-small-cell lung cancer (NSCLC [adenocarcinoma, adenosquamous, or squamous]), head and neck squamous cell carcinoma (HNSCC), urothelial cancer, or malignant melanoma who have exhausted or declined available standard therapy. - Subjects progressing on previous treatment with a checkpoint inhibitor targeting thePD-1/PD-L1 pathway, alone or in combination with chemotherapy after previously having achieved stable disease or better and stayed on such therapy for ≥12 weeks. - Primary or metastatic lesion suitable for biopsy and willingness to undergo repeat biopsies as appropriate. - Willing and able to provide intravenous access for the administration of the study drug and for blood sampling/testing. Inclusion Criteria (Part 2): - Subjects with histologically confirmed non-squamous metastatic (stage IV) NSCLC, without option for locoregional treatment with curative intent. - Subjects who have not received prior systemic anti-cancer therapy for the locally advanced or metastatic NSCLC. Subjects who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease. - Ability to safety undergo pre-treatment (if no archival biopsy is available) and on-treatment tumor biopsies. - Subject consents to retrieval of archival tumor tissue for screening in case no fresh biopsy is performed during screening. - Willing and able to provide intravenous access for the administration of the study drug and for blood sampling/testing. Exclusion Criteria (Parts 1 and 2): - Subjects with NSCLC tumors with genetic alteration or mutation, for which FDA-approved targeted therapy is available. - Treatment with systemic anticancer treatments, investigational products, or major surgery within 4 weeks before first dose of study drug or 5 half-lives, whichever is shorter. Subjects should have recovered from previous treatment toxicity (except hair loss and peripheral neuropathy). - History of uncontrolled brain metastasis. - Subject has received extended field radiotherapy ≤4 weeks before the start of treatment (≤2 weeks for limited field radiation to alleviate symptoms), and who has not recovered from related side effects of such therapy (except for hair loss). - Subjects who have previously experienced an immune-related adverse event (irAE) to pembrolizumab, for which permanent discontinuation is required. Subjects without a formal contraindication due to previous irAE are not eligible if the AE has not resolved or requires steroids (>10 mg prednisone-equivalent per day) for ongoing management. - Subjects with active severe infection requiring oral antibiotics. - Clinical evidence of an active second invasive malignancy with the exception of stable prostate cancer on watchful waiting. - Uncontrolled or significant cardiovascular disease. - History of autoimmune disease requiring systemic immunosuppressive therapy (daily prednisone equivalent doses >10 mg/day). - HIV patients can be enrolled if the infection is adequately controlled. - Known bleeding disorder or coagulopathy. Subjects on stable anticoagulant therapy are allowed. - Known or suspected allergy to study treatment or related products. - Women who are pregnant or breastfeeding, or trying to become pregnant. - Patients with chronic viral hepatitis. Exclusion criteria (Part 2): - Previous therapy with immunotherapy (anti-PD-1, anti-PD-L1, and anti-PD-L2, anti-CTLA-4, or other approved or investigational checkpoint-inhibitors). - Subject is unable or unwilling to take folic acid or vitamin B12 supplementation. - Subject is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDS), other than an aspirin dose ≤ 1.3 g per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam). Other protocol-defined inclusion/exclusion criteria may apply.
18 Years - N/A
Accepts Healthy Volunteers
Ignacio Garcia-Ribas, MD, PhD, ,
Ignacio Garcia-Ribas, MD, PhD, Study Director, Cantargia AB